Annual report pursuant to Section 13 and 15(d)

Note 3 - Discontinued Operations (Tables)

v3.8.0.1
Note 3 - Discontinued Operations (Tables)
 12 Months Ended
Dec. 31, 2017
Notes Tables  
Disposal Groups, Including Discontinued Operations [Table Text Block]
   
December
31,
201
7
    
December 31,
201
6
  
Accounts and other receivables
   $
—
     $
1,598,994
  
Inventory, net
    
—
      
1,374,618
  
Prepaid expenses
    
—
      
170,635
  
Assets associated with discontinued operations, current
    
—
      
3,144,247
  
Property and equipment, net of accumulated depreciation
    
—
      
70,973
  
Patents and trademarks, net of accumulated amortization
    
—
      
34,282
  
Assets associated with discontinued operations, noncurrent
    
—
      
105,255
  
Total assets associated with discontinued operations
   $
—
     $
3,249,502
  
                 
Accounts payable
   $
—
     $
1,957,938
  
Accrued liabilities
    
7,092
      
607,659
  
Deferred revenue
    
—
      
2,300,000
  
Liabilities associated with discontinued operations, current
    
7,092
      
4,865,597
  
Other liabilities
    
—
      
—
  
Total l
iabilities associated with discontinued operations
   $
7,092
     $
4,865,597
  
   
Years Ended December 31,
  
   
2017
    
2016
    
2015
  
Revenue:
                        
Lymphoseek sales revenue
   $
2,917,213
     $
16,997,497
     $
10,235,277
  
Royalties on GDS Business
    
—
      
—
      
1,194,660
  
Grant and other revenue
    
—
      
575
      
669
  
Total revenue
    
2,917,213
      
16,998,072
      
11,430,606
  
Cost of goods sold
    
364,192
      
2,234,780
      
1,751,537
  
Gross profit
    
2,553,021
      
14,763,292
      
9,679,069
  
Operating expenses:
                        
Research and development
    
383,446
      
1,744,496
      
2,225,004
  
Selling, general and administrative
    
961,873
      
5,093,529
      
6,369,183
  
Total operating expenses
    
1,345,319
      
6,838,025
      
8,594,187
  
Income from discontinued operations
    
1,207,702
      
7,925,267
      
1,084,882
  
Interest expense
    
(1,706,491
)
    
(14,856,404
)
    
(5,603,820
)
Income (loss) before income taxes
    
(498,789
)
    
(6,931,137
)
    
(4,518,938
)
Benefit from (provision for) income taxes
    
8,031
      
—
      
—
  
Loss from discontinued operations
   $
(490,758
)
   $
(6,931,137
)
   $
(4,518,938
)